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Munich, Neuherberg, and Garching, Germany; and Jeddah, Saudi ArabiaOBJECTIVES The goal of this study was to evaluate the feasibility of [18F]Galacto-RGD positron emis-
sion tomography (PET)/computed tomography (CT) imaging of avb3 expression in human carotid plaques.
BACKGROUND The integrin avb3 is expressed by macrophages and angiogenic endothelial cells in
atherosclerotic lesions and thus is a marker of plaque inﬂammation and, potentially, of plaque vulnera-
bility. [18F]Galacto-RGD is a PET tracer binding speciﬁcally to avb3. Therefore, [18F]Galacto-RGD PET/CT
imaging of avb3 expression in human carotid plaques might provide a novel noninvasive biomarker
of plaque vulnerability.
METHODS [18F]Galacto-RGD PET/CT imaging was performed in 10 patients with high-grade carotid ar-
tery stenosis scheduled for carotid endarterectomy. Tracer uptakewasmeasured in the stenotic areas of the
carotid arteries, as well as on the contralateral side, and was corrected for blood pool activity, measured in
the distal common carotid artery (target-to-background [TB] ratio). TB ratio was correlated with immuno-
histochemistry of avb3 expression (LM609), macrophage density (CD68), and microvessel density (CD31)
of the surgical specimen. In addition, ex vivo autoradiography of the surgical specimen with [18F]Gal-
acto-RGD and competition experiments with an unlabeled avb3-speciﬁc RGD peptide were performed.
RESULTS [18F]Galacto-RGD PET/CT showed signiﬁcantly higher TB ratios in stenotic areas compared
with nonstenotic areas (p ¼ 0.01). TB ratios correlated signiﬁcantly with avb3 expression (R ¼ 0.787,
p ¼ 0.026) and intensity of ex vivo autoradiography (R ¼ 0.733, p ¼ 0.038). Binding to atherosclerotic
plaques was efﬁciently blocked in ex vivo competition experiments. A weak-to-moderate correlation
was found with macrophage density (R ¼ 0.367, p ¼ 0.299) and microvessel density (R ¼ 0.479,
p ¼ 0.176), which did not reach statistical signiﬁcance.
CONCLUSIONS [18F]Galacto-RGD PET/CT shows speciﬁc tracer accumulation in human atheroscle-
rotic carotid plaques, which correlates with avb3 expression. Based on these initial data, larger prospec-
tive studies are now warranted to evaluate the potential of molecular imaging of avb3 expression for
assessment of plaque inﬂammation in patients. (J Am Coll Cardiol Img 2014;7:178–87) ª 2014 by
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179troke is a leading cause of long-term disability for imaging the level of avb3 expression in tumors
and the fourth leading cause of death in theA B B R E V I A T I O N S
A N D A C R O N YM S
CCA = common carotid artery
[18F]FDG = ﬂuorine-
18-ﬂuorodeoxyglucose
ICA = internal carotid artery
MRI = magnetic resonance
imaging
ROI = region of interest
SUV = standardized
uptake value
TB = target-to-backgroundUnited States (1). Atherosclerosis is the
major reason for most clinical cardiovascular
events such as stroke, and inﬂammation is an
important feature of atherosclerotic plaque pro-
gression and vulnerability (2,3). More recently,
intraplaque angiogenesis has also been implicated in
rapid plaque growth and plaque rupture, which are
of special relevance in carotid atherosclerotic lesions
(4,5). Noninvasive imaging of inﬂammation and
angiogenesis within atherosclerotic lesions may
therefore be useful to predict future risk of plaque
rupture and allow monitoring of antiatherosclerotic
therapies, such as with magnetic resonance imaging
(MRI) (6,7). However, despite the vast improve-
ments in plaque imaging with MRI, radiotracer
approaches might still provide useful additional in-
formation because they are more focused on quan-
tifying speciﬁc biological processes. Moreover, MRI
signals are much harder to quantify compared with
radiotracer techniques such as positron emission to-
mography (PET). Thus, PET and MRI can provide
synergistic information with respect to plaque im-
aging, and combining the data from each technique
might even further improve our knowledge of plaque
biology and vulnerability (8). This information may
be of special relevance for use in the now clinically
available hybrid PET/MRI scanners (9).
Multiple experimental and human studies have
provided evidence that PET with the use of ﬂuo-
rine-18-ﬂuorodeoxyglucose ([18F]FDG), a glucose
analogue that is taken up by macrophages, could
provide an index of inﬂammation in atherosclerotic
lesions (10–12). In atherosclerotic lesions, both
macrophages and activated endothelial cells can
express high levels of the avb3 integrin, a cell sur-
face glycoprotein receptor (13–16). Therefore, avb3
expression potentially is a combined marker of both
inﬂammation and angiogenesis in atherosclerotic
lesions. Imaging of avb3 integrin expression might
thus be useful as a noninvasive in vivo surrogate
parameter of plaque vulnerability (17,18). [18F]
Galacto-RGD is a peptide tracer for PET imaging
with highly speciﬁc binding to the avb3 integrin
(19). Recently, speciﬁc uptake of the avb3-targeted
tracers [68Ga]DOTA-RGD and [18F]Galacto-
RGD has been shown in atherosclerotic plaques in
the aorta of hypercholesterolemic mice (20,21).
Moreover, [18F]Galacto-RGD uptake in these
plaques could be reduced by diet intervention,
demonstrating the potential of avb3 imaging for
evaluation of therapy response (22). Clinically, [18F]
Galacto-RGD PET has been successfully validated(23–25). However, most tumor lesions in patients
were substantially larger than atherosclerotic lesions,
and the spatial resolution of clinical PET and PET/
computed tomography (CT) imaging is limited
(26). Thus, the potential of imaging avb3 expres-
sion in atherosclerotic lesions with [18F]Galacto-
RGD PET in the clinical setting remains unknown.
In the present study, we evaluated the general
technical feasibility of PET/CT imaging of avb3
expression in patients with carotid stenosis who
were scheduled for endarterectomy. We correlated
the in vivo uptake of [18F]Galacto-RGD in carotid
plaques with histopathological data and in vitro
autoradiography of the surgery specimen.
METHODS
Patients. Informed written consent was obtained
from all patients. The ethics committee of our
university approved the study protocol.
Ten patients with high-grade carotid artery
stenosis scheduled for carotid endarterec-
tomy were examined within 2 weeks before
the operation with [18F]Galacto-RGD
PET/CT (mean age 68.5  6.6 years;
range 55 to 79 years). Inclusion criteria
were carotid artery stenosis >70% in
asymptomatic patients and carotid artery
stenosis >50% in symptomatic patients.
Further inclusion criteria were age >40
years and the ability to provide written and
informed consent. Exclusion criteria were
pregnancy, lactation period, and impaired
renal function (serum creatinine level >1.2 mg/dl).
All patients underwent MR angiography or CT
angiography and clinical examination, including
Doppler ultrasound of the carotid arteries, before
operation.
Radiopharmaceuticals. Synthesis of the precursor
and subsequent [18F]-labeling of Galacto-RGD was
conducted as described previously (27).
[18F]Galacto-RGD PET/CT imaging. Imaging was
performed with a Biograph Sensation 16 PET/CT
(Siemens Medical Solution, Forchheim, Germany).
Ninety minutes after injection of [18F]Galacto-
RGD (188  19 MBq), an emission scan was
performed in 3-dimensional mode in the cranio-
caudal direction from the ﬂoor of the mouth to the
upper mediastinum (3-dimensional mode; 1 bed
position, 15-min acquisition time) (Online
Appendix).
Image analysis. The corrected emissions scans were
calibrated to standardized uptake values (SUV)
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180(measured activity concentration [Bq/ml]  body
weight [g]/injected activity [Bq]). Images were
analyzed on a Leonardo workstation (Siemens,
Erlangen, Germany). In the fused PET/CT images,
a region of interest (ROI) was placed in the axial
slice with the maximum tracer accumulation in
projection on the site of the carotid stenosis (carotid
bifurcation or internal carotid artery [ICA]) as
determined using visual analysis. For determination
of the location of the stenosis, PET/CT data were
correlated with MR or CT angiography data.
Another ROI was placed in the carotid artery on the
contralateral side. Finally, another ROI was placed
below the level of the carotid bifurcation in the
nondiseased common carotid artery (CCA) on both
sides to measure unspeciﬁc tracer retention in the
blood pool. The size of the ROIs was adapted to the
size of the vessels and kept smaller than the vessel
diameter to minimize partial volume effects. The
mean SUV of the ROIs was used for further analysis
(SUVmean). Target-to-background ratios (TB ratio)
were calculated by using the following formula:
SUVmean

target

=

0:5  SUVmean left CCA
þ SUVmean right CCA

Results were expressed as percentage of uptake
over blood pool (TB ratio in %).
Thromboendarterectomy and tissue sampling. The
carotid plaque was removed by standard carotid
thromboendarterectomy, excising the intimal part of
the artery together with all plaque components.
Tissue samples were immediately separated into
segments of 3 to 4 mm, embedded in optimum
cutting temperature compound (Tissue-Tek;
Sakura, Zoeterwoude, the Netherlands), snap-
frozen in liquid nitrogen, and stored at –70C
until further analysis.
Autoradiography. In vitro binding of 18F-galacto-
RGD to the carotid plaques was studied by digital
autoradiography of carotid thromboendarterectomy
specimen tissue sections incubated with 18F-gal-
acto-RGD in the presence or absence of an exces-
sive amount of competing tracer, as described earlier
(28) (Online Appendix).
Histological analyses. Tissues samples embedded in
optimum cutting temperature compound were
sectioned by using a cryostat (Leica Microsystems,
Wetzlar, Germany) and placed on electrically
charged glass slides. Histological features of carotid
plaques were studied in tissue sections stained with
hematoxylin/eosin and elastin van Gieson to assess
plaque structure and morphology, elastin, and
collagen content. Stained samples were analyzed byusing light microscopy. Macrophages, endothelial
cells, smooth muscle cells, and integrin avb3 were
detected by immunostaining with the use of the
following primary antibodies: anti-CD31 (clone
JC70A, dilution 1:40; Dako, Hamburg, Germany),
anti-CD68 (clone KP1, dilution 1:2,000; Dako),
anti–smooth muscle actin (clone HHF35; dilution
1:200; Dako), and biotinylated goat anti-mouse
anti-avb3 (Chemicon, Schwalbach, Germany).
After primary antibody incubation, visualization
was performed using either an APAAP ChemMate
or peroxidase/diaminobenzidine ChemMate Detec-
tion Kit (Dako). Biotinylated antibody against avb3
was detected by a streptavidin-horseradish peroxi-
dase-complex (Jackson Immunoresearch Labora-
tories, West Grove, Pennsylvania) and visualized
with diaminobenzidine (Sigma-Aldrich, Munich,
Germany). Unspeciﬁc primary immunoglobulin G
antibodies were used as negative controls. Two ex-
perienced investigators blinded to the source of each
specimen analyzed all images.
Statistical analysis. Signal intensities determined for
the different regions are expressed as mean  SEM
or in box-and-whisker plots. Differences between
the different subgroups were evaluated by using a
Mann-Whitney U test. For linear regression anal-
ysis, Spearman rank correlation coefﬁcient r and the
p value derived from a 2-tailed Student t distribu-
tion were computed. Univariate correlations were
calculated using the Pearson correlation method.
Statistical signiﬁcance was assigned for p < 0.05.
Computations were performed using MedCalc
(MedCalc Software, Mariakerke, Belgium).
RESULTS
[18F]Galacto-RGD PET/CT of atherosclerotic plaques.
There were 4 sites of the carotid bifurcation or ICA
without stenosis (grade 0), 4 with low-grade stenosis
(grade 1), 2 with moderate stenosis (grade 2), 9 with
severe stenosis (grade 3), and 1 near total occlusion
(grade 4) as classiﬁed by using ultrasound and MR
angiography.
In vivo PET/CT imaging demonstrated focal [18F]
Galacto-RGD uptake (>120% TB ratio) in 5 pa-
tients that co-localized with atherosclerotic lesions as
seen on CT imaging (Fig. 1). Mean uptake of [18F]
Galacto-RGD was signiﬁcantly higher in areas of the
CCA or ICA with medium- or high-grade stenosis
compared with areas with none/low-grade stenosis
(p¼ 0.04). Consistent with this ﬁnding, mean uptake
of [18F]Galacto-RGD was signiﬁcantly higher in
areas of the CCA or ICA with a ﬂow velocity >150
cm/s as determined by Doppler ultrasound (Fig. 2).
Figure 1. Patterns of [18F]Galacto-RGD Uptake in High-Grade Stenosis
Comparison of 2 patients with high-grade stenosis of the internal carotid artery (ICA) on the left side (A to D, patient A) and right side (E to H,
patient B). In magnetic resonance (MR) angiography, one can assess the extent of stenosis (A and E; arrows, open tip). The patient with the
left ICA stenosis exhibits focal uptake in the plaque (B, positron emission tomography (PET) alone; C, PET/computed tomography (CT); arrows,
open tip), whereas the patient with stenosis on the right side does not exhibit elevated uptake in the site of stenosis (F, PET alone; G, PET/CT;
arrows, open tip). Note the physiological radiotracer uptake in the salivary glands (submandibular and sublingual glands in B and C; arrows,
closed tip) and in the mucosal lining of the pharynx and larynx (B, C, F, and G; arrows, closed tip). Immunohistochemistry of avb3 expression
in the advanced carotid atherosclerotic plaques (G and H) demonstrate strongly elevated avb3 expression in the plaque in patient A, whereas
there is only little avb3 expression in the plaque in patient B (lumen is marked by asterisk). Bar ¼ 100 mm.
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181However, in the group with medium- or high-grade
stenosis (or higher ﬂow velocity), there was a wide
distribution of tracer uptake, also with no or little
uptake in some stenotic areas.
Correlation to histology. As shown in Figure 3,
histological correlates of [18F]Galacto-RGD uptakep = 0.04
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Figure 2. Analysis of [18F]Galacto-RGD Uptake
Box-and-whisker plots of the tracer uptake of [18F]Galacto-RGD in PET/CT
stenosis or medium- and high-grade stenosis (A). In B, the correspond
Doppler ultrasound in the area of stenosis (cutoff 150 cm/s). Note that
grade stenosis and correspondingly in areas with elevated blood ﬂow.were studied in serial tissue sections of the throm-
boendarterectomy specimen. CD31 as a pan-
endothelial marker demonstrated a strong positive
signal in the endothelial lining of the plaques and on
the plaque neovasculature. CD68 as a marker for
macrophages demonstrated macrophage inﬁltrationp = 0.01
0
10
20
30
40
50
60
T
/
B
 
R
a
t
i
o
 
(
%
)
B
Vmax < 150 cm/s Vmax > 150 cm/s
measured as target-to-background ratio in the areas of no/low-grade
ing values are stratiﬁed according to ﬂow velocity as measured by
tracer uptake was signiﬁcantly higher in areas of medium- and high-
Vmax ¼ maximum initial velocity; other abbreviations as in Figure 1.
Figure 3. Autoradiography and Immunohistochemistry
Autoradiography and immunohistochemistry studies of the plaque of patient A in Figure 1 (A, thick section; E, thin section; I, magniﬁcation).
D shows the T2-weighted axial magnetic resonance imaging (MRI) for comparison, which also shows different layers of plaque composition.
In vitro binding and competition experiments demonstrated speciﬁc binding of [18F]Galacto-RGD to avb3 integrin in the plaques on tissue
sections (B). The binding was efﬁciently blocked on a serial tissue section in the presence of unlabeled cyclic RGD (C). Areas showing the
highest RGD binding (yellow and red) exhibited a high degree of b3 integrin expression (F and J), macrophage inﬁltration (G and K), and
neovascularization (H and L; arrows). Scale bar 1 mm in A to H and 75 mm in I to L. L ¼ lumen; M ¼ rest of media remained after carotid
plaque excision; NC ¼ large necrotic core with lipid deposition and hemorrhage; NV ¼ neovessels; other abbreviations as in Figure 1.
Beer et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 2 , 2 0 1 4
Imaging avb3 in Carotid Disease F E B R U A R Y 2 0 1 4 : 1 7 8 – 8 7
182in the plaques to a variable extent. Immunohisto-
chemical staining for avb3 demonstrated avb3
expression on endothelial cells of intraplaque neo-
vasculature, as well as macrophages. [18F]Galacto-
RGD uptake (TB ratio) correlated signiﬁcantly with
avb3 expression (R ¼ 0.787, p ¼ 0.026). There was
a weak-to-moderate correlation with macrophage
inﬁltration (R ¼ 0.367, p ¼ 0.299), intraplaque
neovasculature (R ¼ 0.479, p ¼ 0.176), and total
plaque cellularity (R ¼ 0.488, p ¼ 0.168) that did
not reach statistical signiﬁcance (Fig. 4). There was
no signiﬁcant correlation with intraplaque elastin
(R ¼ 0.311, p ¼ 0.380) or collagen content
(R ¼ 0.026, p ¼ 0.941). Due to the limited quality
of our fresh frozen specimens, no systematic analysis
of plaque composition was feasible.
Binding of [18F]Galacto-RGD to atherosclerotic
plaques in vitro. Binding of [18F]Galacto-RGD in
atherosclerotic plaques was studied by using ex vivo
autoradiography of the thromboendarterectomy
specimen and compared with in vivo tracer uptake
and immunohistochemistry. Speciﬁcity of [18F]
Galacto-RGD binding in the atherosclerotic pla-
ques was veriﬁed in a displacement study (Figs. 3Band 3C). [18F]Galacto-RGD was found to bind to
the atherosclerotic lesions to a variable extent (mean
PSL/mm2 ¼ 80.0  26.2), and the binding was
efﬁciently and signiﬁcantly reduced in the presence
of an inhibitor, an unlabeled cyclic avb3-speciﬁc
RGD peptide (mean PSL/mm2 ¼ 10.4  3.1).
The ratio of speciﬁc to nonspeciﬁc binding was
approximately 8-fold (7.9  2.0). In vitro [18F]
Galacto-RGD binding to the plaques correlated
strongly and signiﬁcantly with the score of avb3
expression in the corresponding slices of the spec-
imen (R ¼ 0.913, p ¼ 0.010). Moreover, in vitro
[18F]Galacto-RGD binding to the plaques also
correlated signiﬁcantly with in vivo [18F]Galacto-
RGD uptake as measured by using PET/CT im-
aging (R ¼ 0.733, p ¼ 0.038). These data suggest
that in vivo uptake of [18F]Galacto-RGD in PET/
CT is speciﬁc and correlated with avb3 expression
in atherosclerotic lesions.
Uptake of [18F]Galacto-RGD in symptomatic and
asymptomatic lesions. According to the presence of
patient symptoms probably caused by carotid ste-
nosis, lesions were classiﬁed as either symptomatic
(n ¼ 5) or asymptomatic (n ¼ 11). There was no
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Figure 4. Correlation of Tracer Uptake and Immunohistochemistry
Linear regression analysis of [18F]Galacto-RGD uptake in PET/CT measured as target-to-background (TB) ratio and (A) staining intensity of avb3
expression, (C) endothelial cells (CD31), and (D) macrophages (CD68). (B) Shows the correlation of in vivo tracer uptake with the intensity of
autoradiography in vitro. Note that there is a signiﬁcant correlation of in vivo tracer uptake and avb3 expression, as well as tracer uptake
in vivo and in vitro autoradiography. Abbreviations as in Figure 1.
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183signiﬁcant difference in [18F]Galacto-RGD uptake
in PET/CT imaging in symptomatic (mean TB
ratio 21.3  16.7%) or asymptomatic (mean TB
ratio 17.8  15.5%; p ¼ 0.70) lesions (Fig. 5).
D I SCUSS ION
In this study, we demonstrate for the ﬁrst time the
feasibility of [18F]Galacto-RGD PET/CT imaging
to show focal increases in avb3 integrin expression
in atherosclerotic plaques in patients with high-
grade carotid stenosis. [18F]Galacto-RGD uptake
signiﬁcantly correlated with intraplaque avb3
expression and autoradiography and could be spe-
ciﬁcally blocked in in vitro competition experiments.
On the basis of these initial data, future studies on
PET/CT imaging of avb3 integrin expression are
now warranted to further evaluate its role in patients
as a potential biomarker for inﬂammatory activity of
atherosclerotic lesions.
[18F]Galacto-RGD uptake in atherosclerotic plaques.
[18F]Galacto-RGD is a tracer that is based on thecyclic pentapeptide cyclo(-ARG-Gly-Asp-D-Phe-
Val-) developed by Heckmann and Kessler (29). It
shows high afﬁnity and selectivity for avb3 integrin
in vitro as well as receptor-type speciﬁc accumula-
tion in vivo in avb3 integrin–positive tumors in
mouse models and humans (18,23,27). Studies have
indicated sufﬁcient signal intensity for visualizing
increased avb3 integrin expression in benign lesions
such as infarcted myocardium (30,31). However, up
to now, it was unknown whether avb3 expression in
human carotid plaques is sufﬁcient for imaging with
[18F]Galacto-RGD PET. In this study, we found
that focal [18F]Galacto-RGD uptake can be visu-
alized in atherosclerotic lesions in patients by using
PET/CT imaging. As expected, the mean uptake of
[18F]Galacto-RGD in atherosclerotic lesions was
several folds lower than reported for avb3 integrin–
expressing tumors (32–34). This can easily be
explained by the small volume even of relatively
large atherosclerotic plaques compared with most
tumor lesions, which usually were >20 mm in
diameter in the reported studies. Because the spatial
Figure 5. Correlation of Tracer Uptake and Patient Symptoms
Acute ipsilateral cortical ischemia in a patient with intense [18F]Galacto-RGD uptake in a vulnerable carotid plaque. (A) shows the plaque of the
patient with the high-grade stenosis of the left ICA in Figure 1 in a T2-weighted axial MRI slice (arrow, open tip). The MRI-PET image fusion
(B), which is zoomed in on the stenotic left ICA seen in A, shows the tracer uptake in the plaque, which corresponds to the pattern of tracer
uptake in autoradiography in Figure 3B (arrow, open tip; lumen, asterisk). This patient had an acute small ischemia as demonstrated by
diffusion-weighted MRI (in the ipsilateral left parietal cortex [arrow; C, b1000 image; D, apparent diffusion coefﬁcient map]), proving that the
plaque was vulnerable. However, when analyzing all patients for symptomatic or asymptomatic stenosis, there was no signiﬁcant difference
notable between groups (E). Abbreviations as in Figures 1 and 3.
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184resolution of PET is limited, the so-called partial
volume effect artiﬁcially reduces the measured up-
take in lesions smaller than approximately 20 to 25
mm (35). However, despite the small size of
atherosclerotic lesions, our results suggest that
visualization of avb3 integrin expression in human
plaques is generally possible with PET/CT imaging
by using avb3-speciﬁc tracers. It has to be noted,
however, that in our small patient population, the
correlation was relatively loose, so up to now it has
not been clear to what extent tracer uptake and avb3
expression correlate linearly. This is also somewhat
related to the relatively low signal achieved. To
improve uptake and TB ratios, tracer optimization
by multimerization has been shown to increase
signal intensity from avb3 integrin–expressing tis-
sues (36). Moreover, sophisticated algorithms for
partial volume correction might improve the results
from PET and PET/CT imaging (37).
Immunohistochemical correlate of [18F]Galacto-RGD
uptake. Histological and immunohistochemical
analysis demonstrated that uptake of [18F]Galacto-
RGD signiﬁcantly correlated with avb3 expression
in the plaques, which was mainly expressed on
macrophages as well as neovasculature. [18F]Gal-
acto-RGD uptake did not show a correlation withintraplaque elastin, collagen, or cellularity. A weak-
to-moderate correlation was found with macro-
phage density and neovascularization, which did not
reach statistical signiﬁcance. The low number of
samples in the study might, in part, have caused this,
as various preclinical studies have shown a correlation
of avb3 integrin–targeted RGD peptides with
intraplaque macrophage density and/or neo-
vascularization (20,38). However, mice models often
show no substantial intraplaque neovascularization,
limiting direct comparability with human athero-
sclerotic lesions (39–41). In preclinical MRI studies,
enhancement of atherosclerotic vessel wall by
avb3 integrin–targeted nanoparticles was mainly
explained by the presence of angiogenic vessels
around the intima (42). However, MRI nano-
particles remain mainly intravascular due to their
larger size compared with small peptide PET tracers;
thus, they do not target intraplaque macrophages,
limiting direct comparability to our results.
In vitro autoradiography. In vitro autoradiography
of the thromboendarterectomy specimen with [18F]
Galacto-RGD was performed because the speci-
ﬁcity of tracer uptake can be demonstrated with
blocking studies by pre-incubating with excess of
unlabeled target speciﬁc ligands. Moreover, the
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185pattern of tracer distribution can be compared with
immunohistochemistry.
Indeed, [18F]Galacto-RGD uptake could efﬁ-
ciently and signiﬁcantly be blocked by an unlabeled
avb3-speciﬁc cyclic RGD peptide in vitro. More-
over, in vivo uptake of [18F]Galacto-RGDmeasured
by using PET/CT correlated signiﬁcantly with
in vitro autoradiography, which again correlated
strongly and signiﬁcantly with avb3 expression in
the respective slices used for autoradiography. The
more moderate correlation of in vivo [18F]Galacto-
RGD uptake and avb3 expression compared with
in vitro autoradiography and avb3 expression might
be explained by factors additionally inﬂuencing
measured tracer uptake in PET/CT imaging in
patients (e.g., lesion size, partial volume effects,
tracer access to the intraplaque structures) (43).
The data strongly suggest that in vivo uptake of
[18F]Galacto-RGD measured by using PET/CT is
speciﬁc and allows for at least semi-quantitative
noninvasive assessment of the level of avb3
expression in atherosclerotic lesions.
Comparison to other imaging modalities. PET with
[18F]FDG is currently the best-characterized
radiotracer approach for imaging plaque inﬂamma-
tion (44). Compared with [18F]FDG PET, TB
ratios in our study were in the range or only slightly
lower compared with reported data (11,12). More-
over, a recent preclinical study compared [18F]
Galacto-RGD uptake with 3H-DG, an in vitro
analogue of [18F]FDG, and uptake ratios between
plaque and normal vessel wall were comparable for
both tracers (20). Compared with [18F]FDG, which
is only taken up by intraplaque macrophages, [18F]
Galacto-RGD targets both macrophages and
intraplaque neovasculature, which have both been
implicated in progression and rupture of athero-
sclerotic lesions. Moreover, avb3 integrin may be
directly involved in the degradation of the protective
ﬁbrous cap of atherosclerotic lesions because it has
been identiﬁed as a binding moiety that localizes
protease activity, particularly matrix metal-
loproteinase 2, to the cell surface (45,46). Therefore,
[18F]Galacto-RGD PET/CT visualizes several
important features of plaque instability simulta-
neously, which might potentially be advantageous
compared with [18F]FDG (47).
In terms of imaging of avb3 expression with
MRI, the higher resolution of MRI combined with
excellent soft tissue contrast is an advantage
compared with PET (42,48). However, in MRI,
larger absolute amounts of probes usually have to be
used compared with PET. Thus, adverse effects ofmost PET tracers are limited or not present at all.
This facilitates translation of results of PET tracers
into the clinical setting, as was successfully
demonstrated for [18F]Galacto-RGD in this study.
Study limitations. Because it was uncertain whether
a reliable PET signal could be achieved in patients
with atherosclerotic lesions, the present study was
deliberately intended as a feasibility study with a
limited number of patients. However, even in this
small sample, a signiﬁcant correlation of [18F]Gal-
acto-RGD uptake and avb3 expression as well as
autoradiography could be demonstrated. It is
beyond the scope of this study to clarify in detail the
ultimate clinical value of PET/CT imaging of avb3
expression for identifying patients with vulnerable
plaques. The value of such imaging must be
addressed by future larger, prospective studies.
Moreover, due to the unavailability of avb3
antibody for formalin-ﬁxed and parafﬁn-embedded
samples, we were forced to use fresh frozen tissue
for immunohistochemical analyses, which generally
(especially regarding atherosclerotic tissue) result in
markedly lower histological quality. Thus, assess-
ment of plaque stability according to histopathology
was not possible due to the limited quality of the
specimen, which is an important topic to be clariﬁed
in future studies. However, macrophage content and
neovascularization could be assessed, which are also
considered to be crucial factors for plaque
vulnerability.
CONCLUS IONS
We demonstrated that [18F]Galacto-RGD PET/
CT speciﬁcally visualizes elevated integrin avb3
expression in human carotid plaques. On the basis
of these promising preliminary results, further pro-
spective studies must now be conducted to deﬁne
the clinical value of PET/CT or even PET/MR
imaging of avb3 expression for assessment of plaque
vulnerability and patient prognosis concerning
development of symptomatic stenosis.Acknowledgments
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